What Is Bempedoic Acid, and Is It as Good as the Hype?

Updated July 2026

Bempedoic acid, sold as the non-generic Nexletol, is often presented to doctors as the better alternative to statins. It's a real and useful drug, but the push to prescribe it might be overly-reliant on one particular study. Here's what it actually is, what the evidence really shows, and how to read the hype.

What is bempedoic acid?

A once-daily cholesterol-lowering pill that works in the liver through the same pathway as statins, interrupting LDL production, but at an earlier step. Bempedoic acid is a pro-drug – meaning it needs to be activated to exert its action, and that happens in the liver. Because the active drug is then present only in the liver, bempedoic acid doesn't carry the same muscle-ache profile as statins (which are activated already when consumed). This is why Nexletol is often used in people who can't tolerate statins.

How well does bempedoic acid work?

Meaningfully, but not miraculously. In the large CLEAR Outcomes trial of about 14,000 statin-intolerant people, bempedoic acid reduced the combined risk of heart attack, stroke, bypass or stent, and cardiovascular death by about 13%. That's a real, worthwhile benefit, just not the blockbuster some headlines implied. Statins reduce those events by about 33%.

So why tout a "39%" risk reduction?

Because of a sub-analysis. Investigators pulled out the roughly 4,200 participants who didn't yet have heart disease and reported that bempedoic acid cut heart attack and heart-disease death by 39% in that subgroup. That's the number that made news, complete with quotes calling it "frankly startling" and "a wakeup call" to put far more people on the drug.

Why be skeptical of that 39%?

Three reasons:

• Lower-risk people (no established heart disease) should see a smaller absolute effect than the higher-risk overall group, not a larger one. An outsize result in the low-risk subset is backwards from what you'd expect.
• The subgroup quietly changed the scorecard. The full trial measured four combined outcomes; the 4,200-person analysis looked at only two of them (heart attack and heart-disease death), dropping stroke and bypass/stent. Would the result have been as dramatic with all four? We'll never know.
• Slicing a trial into subgroups after the fact invites chance findings. In one famous aspirin trial, breaking patients down by astrological sign showed everyone benefited except Geminis and Libras. As a Libra, I can tell you that's a coincidence, not biology. Add the drug-company's incentive to produce a blockbuster, and a healthy dose of skepticism is warranted.

What are the downsides of bempedoic acid?

It's neither side-effect free nor cheap. It can cause gout, gallstone attacks, and tendon ruptures. Those are uncommon, but a ruptured tendon doesn't undo itself. And at around $400 a month, the price is only justifiable for select patients.

So where does that leave you?

Bempedoic acid is a legitimate option, especially if you can't tolerate statins and need more lowering than diet alone provides. But it treats a number, carries real cost and real risks, and its evidence is solid-but-modest, not miraculous. It's also worth remembering that $400 a month buys a lot of beautiful, health-promoting food, the kind that lowers cholesterol and heart risk while helping prevent the very problems (like gout) that this drug can cause. For the full menu of options, see cholesterol medications beyond statins, and remember that food is the foundation underneath all of them.

If you're new to this site and found this useful, I write one of these evidence-based articles every week. You can get them in your inbox by joining my email list at the bottom of this page. No spam, no requirement to buy anything, just practical knowledge.